Annual General Meeting of Active Biotech AB
June 16 2017 - 2:30AM
PRESS RELEASE
The Annual
General Meeting of Active Biotech was held on June 15, 2017.
In accordance with the Board of Directors'
proposal, it was resolved that no dividend would be paid.
The board members and the managing director were
discharged from liability with respect to their management of the
company for 2016.
In accordance with the Election
Committee's proposal, the Board members Mats Arnhög, Magnhild
Sandberg-Wollheim, Peter Sjöstrand and Peter Thelin were
re-elected. The Meeting also resolved to re-elect Mats Arnhög as
Chairman of the Board. KPMG AB was re-elected as auditor.
Furthermore, in accordance with the Election
Committee's proposal, the Meeting resolved that the Election
Committee shall be composed of representatives for the three
largest owners, as per the end of September, 2017, as well as the
Chairman of the Board.
The Meeting approved the Board's proposal
concerning guidelines for remuneration to the President and other
senior executives. The guidelines essentially conform to the
principles applied to date.
In accordance with the Board's proposal, the
Meeting resolved to authorize the Board, for a period that does not
extend past the date of the next Annual General Meeting, to resolve
on the issue of not more than nine million new shares and/or
convertibles with the corresponding dilution effect, with or
without pre-emptive rights for the company's shareholders.
In accordance with the Board's proposal, the
Meeting resolved to reduce the company's share capital by
approximately SEK 364,464,039 for allocation to unrestricted
shareholders' equity, without cancellation of shares, and to reduce
the statutory reserve by approximately SEK 118,870,784, for
allocation to unrestricted shareholders' equity. In addition
thereto, the Meeting resolved to amend the articles of association
as proposed by the Board.
Lund, June 16, 2017
Active Biotech AB (publ)
Tomas Leanderson
President and CEO
For further information, please
contact:
Hans Kolam, CFO
Tel +46 46 19 20 44
Active Biotech AB (publ)
(Nasdaq Stockholm: ACTI) is a biotechnology company with focus on
neurodegenerative/ inflammatory diseases and cancer. Laquinimod, an
orally administered small molecule with unique immunomodulatory
properties, is in Phase 2 development for the treatment of primary
progressive multiple sclerosis and Huntington's disease. Anyara,
cancer immunotherapy, previously in clinical Phase 1-2/3
development in patients with pancreatic-, lung- or renal cancer.
Furthermore, commercial activities are conducted for the
tasquinimod, paquinimod and SILC projects. Please visit
www.activebiotech.com for more information.
Active Biotech AB
(Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund, Sweden
Tel: +46 (0)46 19 20 00
Annual General Meeting of Active
Biotech AB
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Active Biotech via Globenewswire
Actividentity Corp (MM) (NASDAQ:ACTI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Actividentity Corp (MM) (NASDAQ:ACTI)
Historical Stock Chart
From Apr 2023 to Apr 2024